Pharmacogenomic signatures of response to etanercept therapy for psoriasis

AC Foulkes; DF Carr; Ali Alsharqi; Richard Parslew; Munir Pirmohamed; NJ Reynolds; MJ Donaldson; Michael R. Barnes; Christopher Em Griffiths; Richard B. Warren

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2014

Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept

Christopher Em Griffiths, Wolfram Sterry, F Brock, M. Dilleen, D. Stefanidis, Jean‐Michel Germain, Lotus Mallbris

Article2010

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

Christopher Em Griffiths, Bruce Strober, Peter van de Kerkhof, Vincent Ho, Roseanne Fidelus-Gort, Newman Yeilding, Cynthia Guzzo, Yichuan Xia, B. Zhou, Shu Li, Lisa T. Dooley, Neil Goldstein, Alan Menter

Letter2015

Impact of early vs. late disease onset on treatment response to etanercept in patients with psoriasis

Christopher Em Griffiths, Enno Christophers, Annette Szumski, Heather Jones, Lotus Mallbris

Article2016

039 Systems biology approach to the analysis of pharmacogenomic data in psoriasis

Amy Foulkes, David Watson, Nicholas J. W. Rattray, Michael Donaldson, Royston Goodacre, Nick J. Reynolds, Christopher Em Griffiths, Richard B. Warren, Michael R. Barnes

Article2016

024 Psoriasis Stratification to Optimise Relevant Therapy (PSORT): Clinical and demographic predictors of biologic response for psoriasis

Richard B. Warren, David Burden, Barbara Tomenson, Moetaza M. Soliman, Richard Emsley, Christopher Em Griffiths, Catherine Smith